Novartis receives EU approval for Ilaris® in active Systemic Juvenile …

Study 1, a 4-week, randomized , double-blind, placebo- controlled study , involved 84 patients between the ages of 2 and 19 years with active SJIA[1],[2].

More here:
Novartis receives EU approval for Ilaris® in active Systemic Juvenile …

No comments yet.

TOP